Evaluation of an (111)In-DOTA-rhenium cyclized alpha-MSH analog: a novel cyclic-peptide analog with improved tumor-targeting properties.

UNLABELLED The aim of this study was to examine the effect of rhenium-mediated peptide cyclization on melanoma targeting, biodistribution, and clearance kinetics of the alpha-melanocyte-stimulating hormone (alpha-MSH) analog 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) coupled ReO-cyclized [Cys(3,4,10),D-Phe(7)]alpha-MSH(3-13) (DOTA-ReCCMSH). METHODS DOTA-ReCCMSH was compared with its reduced nonmetalated linear homolog, DOTA-CCMSH, and an analog in which rhenium cyclization was replaced by disulfide bond cyclization, DOTA-[Cys(4,10),D-Phe(7)]alpha-MSH(4-13) (CMSH). DOTA was also conjugated to the amino terminus of one of the highest-affinity alpha-MSH receptor-binding peptides, [Nle(4),D-Phe(7)]alpha-MSH (NDP), as a linear peptide standard. The DOTA-conjugated alpha-MSH analogs were radiolabeled with (111)In and examined for their in vitro receptor-binding affinity with B16/F1 murine melanoma cells, and their in vivo biodistribution properties were evaluated and compared in melanoma tumor-bearing C57 mice. RESULTS The tumor uptake values of (111)In-DOTA-ReCCMSH were significantly higher than those of the other closely related (111)In-DOTA-alpha-MSH conjugates. Even at 24 h after injection, a comparison of the tumor uptake values for (111)In-DOTA-coupled ReCCMSH (4.86 +/- 1.52 percentage injected dose [%ID]/g), CCMSH (1.91 +/- 0.56 %ID/g), CMSH (3.09 +/- 0.32 %ID/g), and NDP (2.47 +/- 0.79 %ID/g) highlighted the high tumor retention property of ReCCMSH. Rhenium-coordinated cyclization resulted in less renal radioactivity accumulation of (111)In-DOTA-ReCCMSH (8.98 +/- 0.82 %ID/g) than of (111)In-DOTA-CCMSH (63.2 +/- 15.6 %ID/g), (111)In-DOTA-CMSH (38.4 +/- 3.6 %ID/g), and (111)In-DOTA-NDP (12.0 +/- 1.96 %ID/g) at 2 h after injection and significantly increased its clearance into the urine (92 %ID at 2 h after injection). A high radioactivity uptake ratio of tumor to normal tissue was obtained for (111)In-DOTA-ReCCMSH (e.g., 489, 159, 100, and 49 for blood, muscle, lung, and liver, respectively, at 4 h after injection). CONCLUSION The novel ReO-coordinated cyclic structure of DOTA-ReCCMSH contributes significantly to its enhanced tumor-targeting and renal clearance properties and makes DOTAReCCMSH an excellent candidate for melanoma radiodetection and radiotherapy.

[1]  P. Beaumier,et al.  Targeted proteins for diagnostic imaging: does chemistry make a difference? , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  T. Maughan,et al.  The use of a chelating derivative of alpha melanocyte stimulating hormone for the clinical imaging of malignant melanoma. , 1992, The British journal of radiology.

[3]  A. Eberle,et al.  Homologous and Heterologous Regulation of α-Melanocyte-stimulating Hormone Receptors in Human and Mouse Melanoma Cell Lines , 1994 .

[4]  C. Mogensen,et al.  Studies on renal tubular protein reabsorption: partial and near complete inhibition by certain amino acids. , 1977, Scandinavian journal of clinical and laboratory investigation.

[5]  C. G. Knight,et al.  A chelating derivative of alpha-melanocyte stimulating hormone as a potential imaging agent for malignant melanoma. , 1990, British Journal of Cancer.

[6]  J. B. Tatro,et al.  Specific receptors for alpha-melanocyte-stimulating hormone are widely distributed in tissues of rodents. , 1987, Endocrinology.

[7]  A. Eberle,et al.  [111In]‐DTPA‐labeled analogues of α‐melanocyte‐stimulating hormone for melanoma targeting: Receptor binding in vitro and in vivo , 1994, International journal of cancer.

[8]  I. Pastan,et al.  Factors influencing the in vivo pharmacokinetics of peptides and antibody fragments: the pharmacokinetics of two PET-labeled low molecular weight proteins. , 1997, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[9]  N. Kotite,et al.  Lysine reduces renal accumulation of radioactivity associated with injection of the [177Lu]alpha-[2-(4-aminophenyl) ethyl]-1,4,7,10-tetraaza-cyclodecane-1,4,7,10-tetraacetic acid-CC49 Fab radioimmunoconjugate. , 1995, Cancer research.

[10]  R. Minchin,et al.  Binding and internalization of the melanocyte stimulating hormone receptor ligand [Nle4, D-Phe7] alpha-MSH in B16 melanoma cells. , 1996, The international journal of biochemistry & cell biology.

[11]  M. Atkins,et al.  Melanotropin receptors demonstrated in situ in human melanoma. , 1990, The Journal of clinical investigation.

[12]  Enhanced binding and inertness to dehalogenation of alpha-melanotropic peptides labeled using N-succinimidyl 3-iodobenzoate. , 1996 .

[13]  M. Zalutsky,et al.  Fluorine-18-labeled [Nle4,d-Phe7]-α-MSH, an α-melanocyte stimulating hormone analogue , 1997 .

[14]  S. Jurisson,et al.  Design and characterization of alpha-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[15]  G. Denardo,et al.  Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  U. Mazzi,et al.  Technetium and rhenium in chemistry and nuclear medicine , 1990 .

[17]  M. Brechbiel,et al.  Lead(II) complexes of 1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetate: solution chemistry and application to tumor localization with 203Pb labeled monoclonal antibodies , 1995 .

[18]  S. Mirzadeh,et al.  Improved in vivo stability and tumor targeting of bismuth-labeled antibody. , 1990, Cancer research.

[19]  J. Knapowski,et al.  Renal reabsorption of amino acids. , 1962, The American journal of physiology.

[20]  A. Eberle,et al.  Characterization of Receptors for α-Melanocyte-stimulating Hormone on Human Melanoma Cells , 1989 .

[21]  S. Jurisson,et al.  In vivo evaluation of 99mTc/188Re-labeled linear alpha-melanocyte stimulating hormone analogs for specific melanoma targeting. , 1999, Nuclear medicine and biology.

[22]  V. Hruby,et al.  4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[23]  E. Krenning,et al.  Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  A. Eberle,et al.  RADIORECEPTOR ASSAY FOR a-MSH USING MOUSE 816 MELANOMA CELLS+ , 1988 .

[25]  S. Jurisson,et al.  Melanoma-targeting properties of (99m)technetium-labeled cyclic alpha-melanocyte-stimulating hormone peptide analogues. , 2000, Cancer research.